These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20835371)

  • 21. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
    Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
    J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.
    Jones CK; Byun N; Bubser M
    Neuropsychopharmacology; 2012 Jan; 37(1):16-42. PubMed ID: 21956443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor.
    Leach K; Davey AE; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2011 May; 79(5):855-65. PubMed ID: 21300722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and Development of Muscarinic Acetylcholine M
    Takai K; Enomoto T
    Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.
    Ma L; Seager MA; Wittmann M; Jacobson M; Bickel D; Burno M; Jones K; Graufelds VK; Xu G; Pearson M; McCampbell A; Gaspar R; Shughrue P; Danziger A; Regan C; Flick R; Pascarella D; Garson S; Doran S; Kreatsoulas C; Veng L; Lindsley CW; Shipe W; Kuduk S; Sur C; Kinney G; Seabrook GR; Ray WJ
    Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15950-5. PubMed ID: 19717450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
    Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
    Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).
    Nawaratne V; Leach K; Suratman N; Loiacono RE; Felder CC; Armbruster BN; Roth BL; Sexton PM; Christopoulos A
    Mol Pharmacol; 2008 Oct; 74(4):1119-31. PubMed ID: 18628403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
    Lanzafame AA; Sexton PM; Christopoulos A
    Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
    May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic regulation of m2 muscarinic acetylcholine receptor desensitization and sequestration by G protein-coupled receptor kinase-2 and beta-arrestin-1.
    Schlador ML; Nathanson NM
    J Biol Chem; 1997 Jul; 272(30):18882-90. PubMed ID: 9228066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators.
    Berizzi AE; Gentry PR; Rueda P; Den Hoedt S; Sexton PM; Langmead CJ; Christopoulos A
    Mol Pharmacol; 2016 Oct; 90(4):427-36. PubMed ID: 27461343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias.
    van der Westhuizen ET; Choy KHC; Valant C; McKenzie-Nickson S; Bradley SJ; Tobin AB; Sexton PM; Christopoulos A
    Front Pharmacol; 2020; 11():606656. PubMed ID: 33584282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.
    Lebois EP; Bridges TM; Lewis LM; Dawson ES; Kane AS; Xiang Z; Jadhav SB; Yin H; Kennedy JP; Meiler J; Niswender CM; Jones CK; Conn PJ; Weaver CD; Lindsley CW
    ACS Chem Neurosci; 2010; 1(2):104-121. PubMed ID: 21961051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
    Teal LB; Gould RW; Felts AS; Jones CK
    Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allosteric modulators and selective agonists of muscarinic receptors.
    Holzgrabe U; De Amici M; Mohr K
    J Mol Neurosci; 2006; 30(1-2):165-8. PubMed ID: 17192667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
    Langmead CJ; Austin NE; Branch CL; Brown JT; Buchanan KA; Davies CH; Forbes IT; Fry VA; Hagan JJ; Herdon HJ; Jones GA; Jeggo R; Kew JN; Mazzali A; Melarange R; Patel N; Pardoe J; Randall AD; Roberts C; Roopun A; Starr KR; Teriakidis A; Wood MD; Whittington M; Wu Z; Watson J
    Br J Pharmacol; 2008 Jul; 154(5):1104-15. PubMed ID: 18454168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
    Valant C; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal structure of the M
    Vuckovic Z; Gentry PR; Berizzi AE; Hirata K; Varghese S; Thompson G; van der Westhuizen ET; Burger WAC; Rahmani R; Valant C; Langmead CJ; Lindsley CW; Baell JB; Tobin AB; Sexton PM; Christopoulos A; Thal DM
    Proc Natl Acad Sci U S A; 2019 Dec; 116(51):26001-26007. PubMed ID: 31772027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based discovery of selective positive allosteric modulators of antagonists for the M
    Korczynska M; Clark MJ; Valant C; Xu J; Moo EV; Albold S; Weiss DR; Torosyan H; Huang W; Kruse AC; Lyda BR; May LT; Baltos JA; Sexton PM; Kobilka BK; Christopoulos A; Shoichet BK; Sunahara RK
    Proc Natl Acad Sci U S A; 2018 Mar; 115(10):E2419-E2428. PubMed ID: 29453275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.